454 results on '"Akilov, Oleg"'
Search Results
2. Deciphering Tumor Cell Evolution in Cutaneous T-Cell Lymphomas: Distinct Differentiation Trajectories in Mycosis Fungoides and Sézary Syndrome
3. Response to brentuximab vedotin versus physician’s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis
4. Blockade of the Immune Checkpoint CD47 by TTI-621 Potentiates the Response to Anti-PD-L1 in Cutaneous T Cell Lymphoma
5. The pivotal role of cytotoxic NK cells in mediating the therapeutic effect of anti-CD47 therapy in mycosis fungoides
6. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data
7. Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study
8. Research Techniques Made Simple: Skin-Targeted Drug and Vaccine Delivery Using Dissolvable Microneedle Arrays
9. Utility of Low-Dose Duvelisib for Advanced Mycosis Fungoides: A Single-Institution Study
10. The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma
11. The synergistic proapoptotic effect of PARP-1 and HDAC inhibition in cutaneous T-cell lymphoma is mediated via Blimp-1
12. Deciphering Tumor Cell Evolution in Cutaneous T-Cell Lymphomas: Distinct Differentiation Trajectories in Mycosis Fungoides and Sézary Syndrome
13. What Does the Future Hold for Biomarkers of Response to Extracorporeal Photopheresis for Mycosis Fungoides and Sézary Syndrome?
14. CD5+ Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Presenting as an Asymptomatic Nodule
15. Real-world outcomes and tolerability of mogamulizumab monotherapy and multimodality therapy for cutaneous T-cell lymphoma: results from a multicenter retrospective cohort study
16. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
17. Correction to: The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma
18. TCL-458 Real-World Treatment Patterns in Patients With Sézary Syndrome in the United States and the Impact of Covid-19
19. Non-random geographic distribution of patients with cutaneous T-cell lymphoma in the Greater Pittsburgh Area
20. Blockade of the Immune Checkpoint CD47 by TTI-621 Potentiates the Response to Anti−PD-L1 in Cutaneous T-Cell Lymphoma
21. International Society for Cutaneous Lymphomas Pandemic Section (ICLYPS) analysis of cutaneous T-cell lymphoma outcomes during the COVID-19 pandemic: A retrospective cohort study
22. Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa
23. Supplemental Figure 1 from Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies
24. Factors associated with disease-specific life impact in patients with hidradenitis suppurativa: results from the Global VOICE project
25. CD8+ T Lymphocytes in Hypopigmented Mycosis Fungoides: Malignant Cells or Reactive Clone?
26. Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome
27. O-147 - Real-world outcomes and tolerability of mogamulizumab monotherapy and multimodality therapy for cutaneous T-cell lymphoma: results from a multicenter retrospective cohort study
28. Pseudolymphoma of the nipple treated with topical imiquimod and cryotherapy
29. Factors associated with treatment satisfaction in patients with hidradenitis suppurativa: results from the Global VOICE project
30. Dual-Positive CD4/CD8 Primary Cutaneous Peripheral T-Cell Lymphoma Previously Classified as Mycosis Fungoides a Tumor DʼEmblée
31. Safety and Tolerability of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302
32. Blockade of the Immune Checkpoint CD47 By TTI-621 Potentiates the Response to Anti-PD-L1 in Cutaneous T Cell Lymphoma
33. Targeting the CD47-SIRPα Axis: Present Therapies and the Future for Cutaneous T-cell Lymphoma
34. International Society for Cutaneous Lymphomas Pandemic Section (ICLYPS) analysis of cutaneous T-cell lymphoma outcomes during the COVID-19 pandemic: A retrospective cohort study
35. Poster: TCL-458 Real-World Treatment Patterns in Patients With Sézary Syndrome in the United States and the Impact of Covid-19
36. Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
37. Real-world treatment patterns in patients with Sézary syndrome in the United States and the impact of Covid-19.
38. Therapeutic and prognostic significance of PARP‐1 in advanced mycosis fungoides and Sezary syndrome
39. Hypopigmented Mycosis Fungoides with Large Cell Transformation in a Child
40. Repetitive expanded T‐cell receptor clonotypes impart the classic T helper 2 Sézary cell phenotype
41. HSR22-182: Real-World Treatment Patterns Among Patients With Sézary Syndrome in the United States Between 2018 and 2020
42. Exhausted Markers in Cutaneous T-Cell Lymphoma: The Face that Launched a Thousand Ships
43. Understanding Cell Lines, Patient-Derived Xenograft and Genetically Engineered Mouse Models Used to Study Cutaneous T-Cell Lymphoma
44. Effective treatment of mogamulizumab-induced head and neck dermatitis with fluconazole in a patient with peripheral T-Cell lymphoma
45. Interferon-α2b-induced STAT3 suppression in myeloid-derived suppressor cells in mycosis fungoides
46. Clinical Response to Anti-CD47 Immunotherapy Is Associated with Rapid Reduction of Exhausted Bystander CD4+ BTLA+ T Cells in Tumor Microenvironment of Mycosis Fungoides
47. Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies
48. An update on health-related quality of life from the PROCLIPI study
49. International Cutaneous Lymphomas Pandemic Section (ICLYPS) analysis of CTCL outcomes during COVID-19
50. The pivotal role of cytotoxic NK cells in mediating the therapeutic effect of anti-CD47 therapy in mycosis fungoides
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.